177 results on '"Avedissian, Sean N."'
Search Results
2. Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters
3. Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption
4. Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis
5. Establishment of a Four‐Cell In Vitro Blood‐Brain Barrier Model With Human Primary Brain Cells
6. Pre- and Post-Exposure Prophylaxis for HIV in Patients Taking Anti-Seizure Medications
7. Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
8. TISSUE-SPECIFIC METABOLOMIC REPROGRAMMING DETERMINES THE DISEASE PATHOPHYSIOLOGY OF SARS-COV-2 VARIANTS IN HAMSTER MODEL
9. Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options
10. Pharmacologic approaches to HIV-associated neurocognitive disorders
11. Chemotherapy in pediatric brain tumor and the challenge of the blood–brain barrier
12. Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study
13. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
14. Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime
15. ACE-2, TMPRSS2, and Neuropilin-1 Receptor Expression on Human Brain Astrocytes and Pericytes and SARS-CoV-2 Infection Kinetics
16. A novel 4-cell in-vitro blood-brain barrier model and its characterization by confocal microscopy and TEER measurement
17. Neurological complications of SARS-CoV-2 infection: in vitro and in vivo investigations of the CNS penetration of nirmatrelvir/ritonavir
18. Vancomycin Pharmacokinetics in a Pregnancy Rat Model
19. Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients*
20. Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships
21. Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics
22. Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy
23. Early Switch From Vancomycin to Daptomycin in Methicillin-Resistant Staphylococcus aureus Bacteremia: Still More Questions Than Answers
24. Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches
25. Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review
26. The Pharmacodynamic-Toxicodynamic Relationship of AUC and C max in Vancomycin-Induced Kidney Injury in an Animal Model
27. Does renal function matter for polymyxin B?
28. The Pharmacodynamic-Toxicodynamic Relationship of AUC and CMAX in Vancomycin Induced Kidney Injury in an Animal Model
29. Vancomycin‐Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention
30. Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model
31. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model
32. Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?
33. Evaluation of Dose Fractionated Polymyxin B on Acute Kidney Injury: A Translational In Vivo Model
34. Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU
35. Development of population and Bayesian models for applied use in patients receiving cefepime
36. 1569. A Translational Model to Assess the Impact of Polymyxin B Dose Fractionation on Kidney Injury
37. Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model
38. 1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin–Tazobactam
39. Does renal function matter for polymyxin B?
40. 1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
41. Book Review
42. Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury
43. The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients
44. Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model
45. A Review of the Clinical Pharmacokinetics of Polymyxin B
46. Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model and a confirmatory cellular model
47. Understanding the Components, Calculation, and Impact of Monthly and Seasonal Variation of the Standardized Antimicrobial Utilization Ratio (SAAR)
48. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime
49. Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis
50. Book Review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.